Ralfinamide
Ralfinamide is a multimodal drug which is under investigation by Newron Pharmaceuticals for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain.
It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker, N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor.
It has thus far progressed as far as phase IIb/phase III clinical trials. In 2010 it failed a phase II trial for lower back pain. Encouraging Phase II results have been announced for neuropathic pain.
